1. O'Garra, A. et al. The immune response in tuberculosis. Ann. Rev. Immunol. 31, 475–527 (2013).
2. WHO. Global Tuberculosis Report. WHO: Geneva, 2020.
3. Young, D. & Dye, C. The development and impact of tuberculosis vaccines. Cell 124, 683–687 (2006).
4. Corbett, E.L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009–1021 (2003).
5. Getahun, H., Gunneberg, C., Granich, R. & Nunn, P. HIV infection—associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 50, S201–S207 (2010).
6. Straetemans, M., Glaziou, P., Bierrenbach, A.L., Sismanidis, C. & van der Werf, M.J. Assessing tuberculosis case fatality ratio: a meta-analysis. PLoS One 6, e20755 (2011).
7. Waitt, C. & Squire, S. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int. J. Tuberc. Lung Dis. 15, 871–885 (2011).
8. Babu, S. & Nutman, T.B. Helminth-tuberculosis co-infection: an immunologic perspective. Trends Immunol. 37, 597–607 (2016).
9. Bell, L.C.K. & Noursadeghi, M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat. Rev. Microbiol. 16, 80–90 (2018).
10. Mendy, J. et al. Changes in Mycobacterium tuberculosis-specific immunity with influenza co-infection at time of TB diagnosis. Fron. Immunol. 9, 3093 (2019).
11. Díaz, A. & Allen, J.E. Mapping immune response profiles: the emerging scenario from helminth immunology. Eur. J. Immunol. 37, 3319–3326 (2007).
12. Elias, D. et al. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine 23, 1326–1334 (2005).
13. Monin, L. et al. Helminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosis. J. Clin. Invest. 125, 4699–4713 (2015).
14. Jia, L. et al. Mechanisms of severe mortality-associated bacterial co-infections following influenza virus infection. Front. Cell. Infect. Microbiol. 7, 338 (2017).
15. Seki, M. et al. A patient with fulminant influenza-related bacterial pneumonia due to Streptococcus pneumoniae followed by Mycobacterium tuberculosis infection. Intern. Med. 47, 2043–2047 (2008).
16. Tan, C.-K. et al. Coinfection with Mycobacterium tuberculosis and pandemic H1N1 influenza A virus in a patient with lung cancer. J. Microbiol. Immunol. Infect. 44, 316–318 (2011).
17. Didierlaurent, A. et al. Sustained desensitization to bacterial toll-like receptor ligands after resolutionof respiratory influenza infection. J. Exp. Med. 205, 323–329 (2008).
18. Jamieson, A.M. et al. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340, 1230–1234 (2013).
19. Shahangian, A. et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest. 119, 1910–1920 (2009).
20. Small, C.-L. et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J. Immunol. 184, 2048–2056 (2010).
21. Chen, K., Liu, J. & Cao, X. Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J. Autoimmun. 83, 1–11 (2017).
22. Diamond, M.S. & Schoggins, J.W. Host restriction factor screening: let the virus do the work. Cell Host Microbe 14, 229–231 (2013).
23. Boxx, G.M. & Cheng, G. The roles of type I interferon in bacterial infection. Cell Host Microbe 19, 760–769 (2016).
24. Scriba, T.J. et al. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathog. 13, e1006687 (2017).
25. Zak, D.E. et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387, 2312–2322 (2016).
26. Berry, M.P.R. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973 (2010).
27. Bloom, C.I. et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 7, e46191 (2012).
28. Esmail, H. et al. Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 115, E964–E973 (2018).
29. Maertzdorf, J. et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 12, 15–22 (2011).
30. Singhania, A. et al. A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nat. Commun. 9, 2308 (2018).
31. Redford, P.S. et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J. Infect. Dis. 209, 270–274 (2014).
32. Zhang, L., Jiang, X., Pfau, D., Ling, Y. & Nathan, C.F. Type I interferon signaling mediates Mycobacterium tuberculosis–induced macrophage death. J. Exp. Med. 218, e20200887 (2020).
33. Carmona, J. et al. Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS One 8, e67277 (2013).
34. Manca, C. et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proc. Natl. Acad. Sci. U. S. A. 98, 5752–5757 (2001).
35. Manca, C. et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 25, 694–701 (2005).
36. Ordway, D. et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179, 522–531 (2007).
37. Wiens, K.E. & Ernst, J.D. The mechanism for type I interferon induction by Mycobacterium tuberculosis is bacterial strain-dependent. PLoS Pathog. 12, e1005809 (2016).
38. Hilda, J.N., Das, S., Tripathy, S.P. & Hanna, L.E. Role of neutrophils in tuberculosis: a bird's eye view. Innate Immun. 26, 240–247 (2020).
39. Dorhoi, A. et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J. Clin. Investig. 123, 4836–4848 (2013).
40. Gopal, R. et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am. J. Respir. Crit. Care med. 188, 1137–1146 (2013).
41. Nouailles, G. et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J. Clin. Invest. 124, 1268–1282 (2014).
42. Antonelli, L.R. et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Investig. 120, 1674–1682 (2010).
43. Ji, D.X. et al. Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat. Microbiol. 4, 2128–2135 (2019).
44. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015).
45. Pithie, A. et al. Generation of cytolytic T cells in individuals infected by Mycobacterium tuberculosis and vaccinated with BCG. Thorax 47, 695–701 (1992).
46. Delahaye, J.L. et al. BCG-induced T cells shape Mycobacterium tuberculosis infection before reducing the bacterial burden. bioRxiv, 590554 (2019).
47. Dorhoi, A. et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur. J. Immunol. 44, 2380–2393 (2014).
48. Mayer-Barber, K.D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99–103 (2014).
49. Moreira-Teixeira, L. et al. Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis. Nat. Commun. 11, 5566 (2020).
50. Crosby, E.J., Goldschmidt, M.H., Wherry, E.J. & Scott, P. Engagement of NKG2D on bystander memory CD8 T cells promotes increased immunopathology following Leishmania major infection. PLoS Pathog. 10, e1003970 (2014).
51. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: facilitators of cancer and obesity-induced cancer. Ann. Rev. Cancer Biol. 5, 17–38 (2020).
52. Knaul, J.K. et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 190, 1053–1066 (2014).
53. Kumar, N.P. et al. Role of myeloid derived suppressor cells in tuberculosis infection and disease. BMC Infect. Dis. 14, O18 (2014).
54. Ikeda, A. et al. Progression of autoimmune hepatitis is mediated by IL‐18‐producing dendritic cells and hepatic CXCL9 expression in mice. Hepatology 60, 224–236 (2014).
55. Vandercappellen, J., Van Damme, J. & Struyf, S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267, 226–244 (2008).
56. Tamura, T. et al. The role of antigenic peptide in CD4+ T helper phenotype development in a T cell receptor transgenic model. Int. Immunol. 16, 1691–1699 (2004).
57. Reiley, W.W. et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl. Acad. Sci. U. S. A. 105, 10961–10966 (2008).
58. Franciszkiewicz, K., Boissonnas, A., Boutet, M., Combadière, C. & Mami-Chouaib, F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 72, 6325–6332 (2012).
59. Tadolini, M. et al. On tuberculosis and COVID-19 co-infection. Eur. Respir. J. 56, 2002328 (2020).
60. Xu, W. et al. Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection. Immunity 3, 526–541.e527 (2021).
61. Desvignes, L., Wolf, A.J. & Ernst, J.D. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J. Immunol. 188, 6205–6215 (2012).
62. Giacomini, E. et al. IFN‐β improves BCG immunogenicity by acting on DC maturation. J. Leukoc. Biol. 85, 462–468 (2009).
63. Mayer-Barber, K.D. et al. Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 35, 1023–1034 (2011).
64. Stanley, S.A., Johndrow, J.E., Manzanillo, P. & Cox, J.S. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178, 3143–3152 (2007).
65. Urdahl, K., Shafiani, S. & Ernst, J. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. 4, 288–293 (2011).
66. de Paus, R.A. et al. Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β. Cytokine 61, 645–655 (2013).
67. McNab, F.W. et al. Type I IFN induces IL-10 production in an IL-27–independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis–infected macrophages. J. Immunol. 193, 3600–3612 (2014).
68. Mayer‐Barber, K.D. & Sher, A. Cytokine and lipid mediator networks in tuberculosis. Immunol. Rev. 264, 264–275 (2015).
69. Cai, Y. et al. Single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis. EBioMedicine 53, 102686 (2020).
70. Esaulova, E. et al. The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host Microbe 29, 165–178.e168 (2021).
71. Sakai, S. et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma–homing CD4 T cells. J. Immunol. 192, 2965–2969 (2014).
72. Wolf, A.J. et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205, 105–115 (2008).
73. Groom, J.R. & Luster, A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207–215 (2011).
74. Loetscher, M. et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184, 963–969 (1996).
75. Khader, S.A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8, 369–377 (2007).
76. Hasan, Z. et al. Relationship between circulating levels of IFN‐γ, IL‐10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity. Scand. J. Immunol. 69, 259–267 (2009).
77. Kumar, N.P. et al. Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis. Sci. Rep. 9, 1–8 (2019).
78. Farber, J.M. Mig and IP‐10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61, 246–257 (1997).
79. Ohmori, Y., Schreiber, R.D. & Hamilton, T.A. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J. Biol. Chem. 272, 14899–14907 (1997).
80. Ohmori, Y. et al. Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am. J. Pathol. 142, 861–870 (1993).
81. Barrios-Payán, J., Aguilar-León, D., Lascurain-Ledezma, R. & Hernández-Pando, R. Neutrophil participation in early control and immune activation during experimental pulmonary tuberculosis. Gac. Med. Mex. 142, 273–281 (2006).
82. Pedrosa, J. et al. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect. Immun. 68, 577–583 (2000).
83. Kimmey, J.M. et al. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature 528, 565–569 (2015).
84. Lovewell, R.R., Baer, C.E., Mishra, B.B., Smith, C.M. & Sassetti, C.M. Granulocytes act as a niche for Mycobacterium tuberculosis growth. Mucosal Immunol. 14, 229–241 (2020).
85. Mishra, B.B. et al. Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat. Microbiol. 2, 17072 (2017).
86. Eum, S.-Y. et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137, 122–128 (2010).
87. Arriaga, A.K., Orozco, E.H., Aguilar, L.D., Rook, G.A.W. & Pando, R.H. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin. Exp. Immunol. 128, 229–237 (2002).
88. Chakravarty, S.D. et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect. Immun. 76, 916–926 (2008).
89. Nemeth, J. et al. Latent Mycobacterium tuberculosis infection provides protection for the host by changing the activation state of the innate immune system. bioRxiv, 561126 (2019).
90. Pedroza-Roldán, C. & Flores-Valdez, M.A. Recent mouse models and vaccine candidates for preventing chronic/latent tuberculosis infection and its reactivation. Pathog. Dis. 75, ftx079 (2017).
91. Turbic, A., Leong, S.Y. & Turnley, A.M. Chemokines and inflammatory mediators interact to regulate adult murine neural precursor cell proliferation, survival and differentiation. PLoS One 6, e25406 (2011).
92. Nociari, M., Ocheretina, O., Murphy, M. & Falck-Pedersen, E. Adenovirus induction of IRF3 occurs through a binary trigger targeting Jun N-terminal kinase and TBK1 kinase cascades and type I interferon autocrine signaling. J. Virol. 83, 4081–4091 (2009).
93. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
94. Zhang, L. & Nie, Q. scMC learns biological variation through the alignment of multiple single-cell genomics datasets. Genome Biol. 22, 10 (2021).
95. Jeon, B.Y. et al. In vivo characteristics of Korean Beijing Mycobacterium tuberculosis strain K1 in an aerosol challenge model and in the cornell latent tuberculosis model. J. Med. Microbiol. 61, 1373–1379 (2012).
96. Kwon, K.W. et al. Vaccine efficacy of a Mycobacterium tuberculosis Beijing‐specific proline‐glutamic acid (PE) antigen against highly virulent outbreak isolates. FASEB J. 33, 6483–6496 (2019a).
97. Dutko, F.J. & Oldstone, M.B. Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J. Gen. Virol. 64, 1689–1698 (1983).
98. Ahmed, R., Salmi, A., Butler, L.D., Chiller, J.M. & Oldstone, M.B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160, 521–540 (1984).
99. Kwon, K.W. et al. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci. Rep. 9, 1–14 (2019b).
100. Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902.e1821 (2019).
101. Blondel, V.D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech. Theory Exp. 2008, P10008 (2008).